NZ745682A - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer - Google Patents

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Info

Publication number
NZ745682A
NZ745682A NZ74568213A NZ74568213A NZ745682A NZ 745682 A NZ745682 A NZ 745682A NZ 74568213 A NZ74568213 A NZ 74568213A NZ 74568213 A NZ74568213 A NZ 74568213A NZ 745682 A NZ745682 A NZ 745682A
Authority
NZ
New Zealand
Prior art keywords
prostate cancer
resistant prostate
androgens
treatment
compound
Prior art date
Application number
NZ74568213A
Other languages
English (en)
Inventor
Isan Chen
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49293921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ745682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of NZ745682A publication Critical patent/NZ745682A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
NZ74568213A 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer NZ745682A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705900P 2012-09-26 2012-09-26
NZ74445613A NZ744456A (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Publications (1)

Publication Number Publication Date
NZ745682A true NZ745682A (en) 2019-09-27

Family

ID=49293921

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ74568213A NZ745682A (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
NZ705815A NZ705815A (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
NZ74445613A NZ744456A (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ705815A NZ705815A (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
NZ74445613A NZ744456A (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Country Status (35)

Country Link
US (7) US9884054B2 (ja)
EP (3) EP3777845A1 (ja)
JP (4) JP6351597B2 (ja)
KR (3) KR20220025231A (ja)
CN (4) CN104661658A (ja)
AU (4) AU2013323861C1 (ja)
BR (1) BR112015006705A8 (ja)
CA (1) CA2885415C (ja)
CL (1) CL2015000715A1 (ja)
CR (1) CR20150140A (ja)
CY (1) CY1123716T1 (ja)
DK (1) DK3305285T3 (ja)
EA (3) EA202190820A1 (ja)
EC (1) ECSP15011764A (ja)
ES (1) ES2836424T3 (ja)
GT (1) GT201500071A (ja)
HK (2) HK1252867A1 (ja)
HR (1) HRP20201721T1 (ja)
HU (1) HUE051211T2 (ja)
IL (3) IL312316A (ja)
IN (1) IN2015DN02387A (ja)
LT (1) LT3305285T (ja)
MX (2) MX371020B (ja)
MY (1) MY180834A (ja)
NI (1) NI201500042A (ja)
NZ (3) NZ745682A (ja)
PE (1) PE20150765A1 (ja)
PH (3) PH12015500615B1 (ja)
PT (1) PT3305285T (ja)
RS (1) RS60976B1 (ja)
SG (3) SG10201912719TA (ja)
SI (1) SI3305285T1 (ja)
UA (2) UA117663C2 (ja)
WO (1) WO2014052237A1 (ja)
ZA (1) ZA201808499B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3124481T3 (en) 2010-02-16 2018-05-07 Aragon Pharmaceuticals Inc ANDROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
AU2012353660A1 (en) 2011-12-16 2014-06-12 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EA201791251A1 (ru) 2014-12-05 2017-11-30 Арагон Фармасьютикалз, Инк. Противораковые композиции
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
EP3226842B1 (en) * 2014-12-05 2020-11-25 Aragon Pharmaceuticals, Inc. Anticancer compositions
KR101718226B1 (ko) 2015-08-05 2017-03-20 울산대학교 산학협력단 사쿠라소사포닌 화합물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환의 예방 또는 치료용 조성물
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20200070334A (ko) * 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
KR20210153038A (ko) * 2019-01-30 2021-12-16 아라곤 파마슈티컬스, 인코포레이티드 전이성 거세-민감성 전립선암의 치료를 위한 항안드로겐
EP4054572A1 (en) * 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (ja) 1955-08-30
JPS4916937B1 (ja) 1970-01-21 1974-04-25
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
IL55774A (en) 1977-10-28 1982-04-30 Sparamedica Ag Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
DK543178A (da) 1977-12-01 1979-06-02 Wellcome Found Thiodydantoinderivater
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A (fi) 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS60239737A (ja) 1984-05-14 1985-11-28 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
JPH0219363Y2 (ja) 1985-07-31 1990-05-29
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
JP2845384B2 (ja) 1991-11-14 1999-01-13 キヤノン株式会社 画像処理装置
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
DE4316542C1 (de) 1993-05-18 1994-07-21 Schaefer Micomed Gmbh Osteosynthesevorrichtung
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
EP0748220A4 (en) 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
US6124211A (en) 1994-06-14 2000-09-26 Fsi International, Inc. Cleaning method
JPH089997A (ja) 1994-06-28 1996-01-16 Shimadzu Corp 核酸合成法およびそれに用いる試薬キット
ES2155134T3 (es) 1994-07-29 2001-05-01 Suntory Ltd Derivados de imidazolidina y su utilizacion.
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
JP2000514401A (ja) 1995-11-28 2000-10-31 アメリカン・ホーム・プロダクツ・コーポレイション ２―（置換スルファニル）―３，５―ジヒドロ―イミダゾール―４―オン誘導体
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja) 1996-06-20 2005-09-21 株式会社日立製作所 光ファイバセンサ
NZ334236A (en) 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
US5968875A (en) 1997-02-03 1999-10-19 Dow Agrosciences Llc 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with carboxylic acid derivatives on the pyridine ring
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2300151T3 (es) 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
DE19940211A1 (de) 1998-09-22 2000-03-23 Degussa Verfahren zur Herstellung von Imidazolidin-2,4-dionen
WO2000026195A1 (en) 1998-10-30 2000-05-11 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
WO2000044731A1 (en) 1999-01-27 2000-08-03 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
US6350763B1 (en) 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
EP1284973B1 (en) 2000-05-31 2007-06-27 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha l beta 2 mediated cell adhesion
EP1302471B1 (en) 2000-05-31 2006-12-27 Mitsui Chemicals, Inc. Sulfur compound and use thereof
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
US6710037B2 (en) 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
AR036663A1 (es) 2001-10-01 2004-09-22 Bristol Myers Squibb Co Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
EP1576131A4 (en) 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845385B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
JP2006504795A (ja) 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
JP2006510600A (ja) 2002-10-04 2006-03-30 ラボラトワール フルニエ エス・アー ２−チオヒダントインに由来する化合物及び治療におけるその使用
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2004252175A (ja) 2003-02-20 2004-09-09 Kyocera Mita Corp 現像装置、画像形成装置および現像剤の回収方法
EP1634874A4 (en) 2003-06-12 2008-04-02 Chugai Pharmaceutical Co Ltd imidazolidine
RU2333198C2 (ru) 2003-06-12 2008-09-10 Астеллас Фарма Инк. Производные бензамида или фармацевтически приемлемые соли указанного производного, фармацевтическая композиция на их основе и применение
KR20060017791A (ko) 2003-06-12 2006-02-27 노보 노르디스크 에이/에스 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
AU2004298604B2 (en) 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
CA2550447A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
JP2007529533A (ja) 2004-03-15 2007-10-25 ピーティーシー セラピューティクス，インコーポレーテッド 血管新生の抑制に有用なテトラサイクリックカルボリン誘導体
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
JP4912148B2 (ja) 2004-08-03 2012-04-11 中外製薬株式会社 新規イミダゾリジン誘導体
TW200621723A (en) 2004-09-09 2006-07-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
CA2579732C (en) 2004-09-10 2014-08-12 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
KR20070108259A (ko) 2005-03-23 2007-11-08 화이자 프로덕츠 인크. Ｃｔｌａ-4 항체와 호르몬 요법에 의한 전립선암의 치료법
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1893196B2 (en) 2005-05-13 2015-07-29 The Regents of The University of California Diarylhydantoin compound
FR2889189A1 (fr) 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101032486B (zh) 2006-03-08 2011-05-11 张宏 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
SI2368550T1 (sl) 2006-03-27 2013-11-29 The Regents Of The University Of California Modulator androgenskih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenskimi receptorji
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
PL2478907T3 (pl) 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
CA2838089A1 (en) 2006-08-25 2008-02-28 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
EP1905439A1 (en) 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
JP4993996B2 (ja) 2006-10-20 2012-08-08 フクダ電子株式会社 輸液ポンプモニタリング装置
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
WO2009061587A1 (en) 2007-11-09 2009-05-14 Novartis Ag Corticosteroids to treat epothilone or epothilone derivative induced diarrhea
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US20140187641A1 (en) * 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
SG173837A1 (en) 2009-02-24 2011-09-29 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
EP2424537B1 (en) * 2009-04-29 2015-07-08 Bayer Intellectual Property GmbH Substituted imidazoquinoxalines
DK3124481T3 (en) 2010-02-16 2018-05-07 Aragon Pharmaceuticals Inc ANDROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
DK2538785T3 (en) 2010-02-24 2018-05-22 Medivation Prostate Therapeutics Llc Methods for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
JP5998137B2 (ja) * 2010-08-04 2016-09-28 ペルフィキュア ファーマシューティカルズ，インコーポレイテッド 前立腺癌を処置するための併用療法
US20130253035A1 (en) * 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012142208A1 (en) 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
TW201309291A (zh) * 2011-05-17 2013-03-01 Takeda Pharmaceutical 治療癌症之醫藥組合物及方法
CA2843417C (en) 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
WO2013028572A1 (en) * 2011-08-19 2013-02-28 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
KR102035361B1 (ko) * 2011-11-30 2019-11-08 아스트라제네카 아베 암의 병용 치료
US9289436B2 (en) 2012-02-24 2016-03-22 The University Of Chicago Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
FR2989357B1 (fr) 2012-04-12 2016-02-05 Allia Conditionnement unique pour un ensemble sanitaire comprenant une cuvette de wc suspendu et un bati-support associe
RS61988B1 (sr) 2012-06-07 2021-07-30 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
LT3725778T (lt) 2012-09-11 2021-12-27 Medivation Prostate Therapeutics Llc Enzalutamido kompozicijos
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2647462C2 (ru) 2013-04-23 2018-03-15 ЗедЭкс ФАРМА, ЭлЭлСи Композиция, состоящая из множества частиц, покрытых кишечнорастворимой оболочкой и имеющих белковую внутреннюю оболочку
AU2014358850A1 (en) 2013-12-06 2016-06-16 F. Hoffmann-La Roche Ag Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
EP3226842B1 (en) 2014-12-05 2020-11-25 Aragon Pharmaceuticals, Inc. Anticancer compositions
EA201791251A1 (ru) 2014-12-05 2017-11-30 Арагон Фармасьютикалз, Инк. Противораковые композиции
MA41107A (fr) 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CN104857157A (zh) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 一种治疗子宫内膜增殖症的汤剂药物及制备方法
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Also Published As

Publication number Publication date
EA202190820A1 (ru) 2021-10-29
US20210000812A1 (en) 2021-01-07
CA2885415C (en) 2021-06-29
JP2015531373A (ja) 2015-11-02
EP2900224A1 (en) 2015-08-05
HK1252867A1 (zh) 2019-06-06
EA030128B1 (ru) 2018-06-29
US20140088129A1 (en) 2014-03-27
US10799488B2 (en) 2020-10-13
BR112015006705A8 (pt) 2019-08-27
AU2018206695A1 (en) 2018-08-02
AU2018206695C1 (en) 2020-10-22
PE20150765A1 (es) 2015-05-15
PH12018502569A1 (en) 2020-12-07
AU2018206695B2 (en) 2020-07-02
IL237692B2 (en) 2024-07-01
WO2014052237A1 (en) 2014-04-03
US20190269667A1 (en) 2019-09-05
NZ744456A (en) 2019-09-27
ES2836424T3 (es) 2021-06-25
CA2885415A1 (en) 2014-04-03
UA117663C2 (uk) 2018-09-10
AU2013323861A1 (en) 2015-04-02
IN2015DN02387A (ja) 2015-09-04
EP3305285A1 (en) 2018-04-11
US10849888B2 (en) 2020-12-01
AU2013323861C1 (en) 2024-05-02
MX371020B (es) 2020-01-13
SG11201501870RA (en) 2015-04-29
EA201590650A1 (ru) 2015-07-30
EP3305285B1 (en) 2020-09-02
JP7198310B2 (ja) 2022-12-28
NI201500042A (es) 2015-09-02
US9884054B2 (en) 2018-02-06
US10052314B2 (en) 2018-08-21
CN109908114A (zh) 2019-06-21
EP3777845A1 (en) 2021-02-17
EA201890598A3 (ru) 2019-03-29
KR20150070192A (ko) 2015-06-24
MX2015003909A (es) 2016-01-08
HUE051211T2 (hu) 2021-03-01
CY1123716T1 (el) 2022-03-24
KR20220025231A (ko) 2022-03-03
JP2019163288A (ja) 2019-09-26
MY180834A (en) 2020-12-10
US20190269668A1 (en) 2019-09-05
PT3305285T (pt) 2020-11-24
AU2024204555A1 (en) 2024-07-18
PH12015500615A1 (en) 2015-05-11
LT3305285T (lt) 2020-12-10
KR102210825B1 (ko) 2021-02-01
CR20150140A (es) 2015-06-11
DK3305285T3 (da) 2020-10-26
AU2020244431A1 (en) 2020-10-29
RS60976B1 (sr) 2020-11-30
IL312316A (en) 2024-06-01
IL237692B1 (en) 2023-08-01
UA124967C2 (uk) 2021-12-22
HRP20201721T1 (hr) 2021-02-19
SI3305285T1 (sl) 2021-03-31
EA201890598A2 (ru) 2018-07-31
PH12018502570A1 (en) 2020-12-07
SG10201902568YA (en) 2019-04-29
HK1212221A1 (en) 2016-06-10
GT201500071A (es) 2015-12-31
JP2018150365A (ja) 2018-09-27
JP6351597B2 (ja) 2018-07-04
IL304337A (en) 2023-09-01
US20180110764A1 (en) 2018-04-26
BR112015006705A2 (pt) 2017-07-04
MX2019010098A (es) 2019-10-15
EA037806B1 (ru) 2021-05-24
KR20210013342A (ko) 2021-02-03
CN115737643A (zh) 2023-03-07
SG10201912719TA (en) 2020-02-27
AU2013323861B2 (en) 2018-04-19
NZ705815A (en) 2018-08-31
PH12015500615B1 (en) 2015-05-11
ECSP15011764A (es) 2016-01-29
JP6896016B2 (ja) 2021-06-30
US20180318277A1 (en) 2018-11-08
CN109999036A (zh) 2019-07-12
IL237692A0 (en) 2015-05-31
JP2021130718A (ja) 2021-09-09
CL2015000715A1 (es) 2015-12-11
ZA201808499B (en) 2022-12-21
US10799489B2 (en) 2020-10-13
JP6527621B2 (ja) 2019-06-05
USRE49353E1 (en) 2023-01-03
CN104661658A (zh) 2015-05-27

Similar Documents

Publication Publication Date Title
NZ745682A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PH12018500365A1 (en) Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
MX2014005458A (es) Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
PH12015501552A1 (en) Androgen receptor modulator and uses thereof
IN2012DN02081A (ja)
MX352926B (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
MX2013005751A (es) Quinazolincarboxamida azetidinas.
PH12015502342A1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
TN2015000182A1 (en) Stabilized insulin-like growth factor polypeptides
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
MY177715A (en) Use of pidotimod to treat atopic dermatitis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 SEP 2021 BY CPA GLOBAL

Effective date: 20200806

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 SEP 2022 BY CPA GLOBAL

Effective date: 20210812

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 SEP 2023 BY CPA GLOBAL

Effective date: 20220811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 SEP 2024 BY CPA GLOBAL

Effective date: 20230811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 SEP 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240809